Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) - Total Liabilities
Based on the latest financial reports, Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) has total liabilities worth CN¥222.24 Million CNY (≈ $32.52 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shandong Keyuan Pharmaceutical Co. Ltd. A - Total Liabilities Trend (2021–2024)
This chart illustrates how Shandong Keyuan Pharmaceutical Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Shandong Keyuan Pharmaceutical Co. Ltd. to evaluate short-term liquidity relative to the company's equity base.
Shandong Keyuan Pharmaceutical Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Shandong Keyuan Pharmaceutical Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Regional Container Lines Public Company Limited
BK:RCL
|
Thailand | ฿22.24 Billion |
|
Baskent Dogalgaz Dagitim Gayrimenkul Yatirim Ortakligi AS
IS:BASGZ
|
Turkey | TL17.64 Billion |
|
Solareast Holdings Co Ltd
SHG:603366
|
China | CN¥3.33 Billion |
|
New York Mortgage Trust, Inc.
NASDAQ:ADAM
|
USA | $11.33 Billion |
|
Henan Senyuan Electric Co Ltd
SHE:002358
|
China | CN¥3.73 Billion |
|
Capital City Bank Group
NASDAQ:CCBG
|
USA | $3.89 Billion |
|
Hudson Pacific Properties Inc
NYSE:HPP
|
USA | $4.31 Billion |
|
Besalco Sa
SN:BESALCO
|
Chile | CL$1.05 Trillion |
Liability Composition Analysis (2021–2024)
This chart breaks down Shandong Keyuan Pharmaceutical Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Shandong Keyuan Pharmaceutical Co. Ltd. .
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Keyuan Pharmaceutical Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Keyuan Pharmaceutical Co. Ltd. A (2021–2024)
The table below shows the annual total liabilities of Shandong Keyuan Pharmaceutical Co. Ltd. A from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥192.87 Million ≈ $28.22 Million |
+38.83% |
| 2023-12-31 | CN¥138.93 Million ≈ $20.33 Million |
+5.20% |
| 2022-12-31 | CN¥132.06 Million ≈ $19.32 Million |
+2.75% |
| 2021-12-31 | CN¥128.52 Million ≈ $18.81 Million |
-- |
About Shandong Keyuan Pharmaceutical Co. Ltd. A
Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of chemical raw materials and their preparations. It offers gliclazide; metformin hydrochloride; isosorbide mononitrate; isosorbide dinitrate; lansoprazole; mecobalamin; ropivacaine hydrochloride; isoflurane; fluoxetine hydrochloride; clemastine fumarate; chlorpheniramine maleate; esmo… Read more